|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1996-11-12
|
|
pubmed:abstractText |
Currently available therapies for advanced pancreatic cancer offer only palliative benefits, and patients with this disease have a poor prognosis. We undertook a phase II trial of ZD1694 (Tomudex), a quinazoline folate analogue that is a potent and selective thymidylate synthase inhibitor, to determine this analogue's efficacy and safety in patients with advanced pancreatic adenocarcinoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0167-6997
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
355-8
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:8824356-Adult,
pubmed-meshheading:8824356-Aged,
pubmed-meshheading:8824356-Aged, 80 and over,
pubmed-meshheading:8824356-Antimetabolites, Antineoplastic,
pubmed-meshheading:8824356-Enzyme Inhibitors,
pubmed-meshheading:8824356-Female,
pubmed-meshheading:8824356-Humans,
pubmed-meshheading:8824356-Male,
pubmed-meshheading:8824356-Middle Aged,
pubmed-meshheading:8824356-Pancreatic Neoplasms,
pubmed-meshheading:8824356-Quinazolines,
pubmed-meshheading:8824356-Thiophenes,
pubmed-meshheading:8824356-Thymidylate Synthase
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer.
|
|
pubmed:affiliation |
The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study,
Clinical Trial, Phase II
|
